![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: DMXL2 |
Gene summary for DMXL2 |
![]() |
Gene information | Species | Human | Gene symbol | DMXL2 | Gene ID | 23312 |
Gene name | Dmx like 2 | |
Gene Alias | DEE81 | |
Cytomap | 15q21.2 | |
Gene Type | protein-coding | GO ID | GO:0006873 | UniProtAcc | Q8TDJ6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23312 | DMXL2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.96e-16 | -5.42e-01 | 0.0155 |
23312 | DMXL2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.71e-02 | -4.35e-01 | -0.1207 |
23312 | DMXL2 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.40e-11 | -4.42e-01 | -0.1464 |
23312 | DMXL2 | HTA11_866_2000001011 | Human | Colorectum | AD | 5.88e-13 | -4.57e-01 | -0.1001 |
23312 | DMXL2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 7.26e-04 | -3.98e-01 | -0.059 |
23312 | DMXL2 | HTA11_546_2000001011 | Human | Colorectum | AD | 3.90e-02 | -4.77e-01 | -0.0842 |
23312 | DMXL2 | HTA11_866_3004761011 | Human | Colorectum | AD | 3.81e-12 | -5.17e-01 | 0.096 |
23312 | DMXL2 | HTA11_8622_2000001021 | Human | Colorectum | SER | 7.40e-03 | -5.56e-01 | 0.0528 |
23312 | DMXL2 | HTA11_10711_2000001011 | Human | Colorectum | AD | 5.10e-11 | -5.70e-01 | 0.0338 |
23312 | DMXL2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.30e-22 | -5.28e-01 | 0.0674 |
23312 | DMXL2 | HTA11_6818_2000001021 | Human | Colorectum | AD | 8.27e-05 | -5.13e-01 | 0.0588 |
23312 | DMXL2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.88e-08 | -3.73e-01 | 0.294 |
23312 | DMXL2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.49e-16 | -4.79e-01 | 0.3859 |
23312 | DMXL2 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 3.04e-06 | -5.64e-01 | 0.2585 |
23312 | DMXL2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.10e-14 | -4.84e-01 | 0.3005 |
23312 | DMXL2 | F007 | Human | Colorectum | FAP | 2.53e-02 | -3.49e-01 | 0.1176 |
23312 | DMXL2 | A002-C-010 | Human | Colorectum | FAP | 4.45e-13 | -3.77e-01 | 0.242 |
23312 | DMXL2 | A015-C-203 | Human | Colorectum | FAP | 9.02e-20 | -2.97e-01 | -0.1294 |
23312 | DMXL2 | A015-C-204 | Human | Colorectum | FAP | 2.22e-03 | -2.29e-01 | -0.0228 |
23312 | DMXL2 | A002-C-201 | Human | Colorectum | FAP | 2.03e-08 | -2.53e-01 | 0.0324 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00070353 | Esophagus | ESCC | vacuolar acidification | 20/8552 | 24/18723 | 1.69e-04 | 1.11e-03 | 20 |
GO:00514521 | Esophagus | ESCC | intracellular pH reduction | 29/8552 | 42/18723 | 1.87e-03 | 8.46e-03 | 29 |
GO:00458511 | Esophagus | ESCC | pH reduction | 31/8552 | 46/18723 | 2.42e-03 | 1.06e-02 | 31 |
GO:00070351 | Liver | HCC | vacuolar acidification | 18/7958 | 24/18723 | 1.27e-03 | 6.92e-03 | 18 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04142 | Colorectum | SER | Lysosome | 38/1580 | 132/8465 | 2.87e-03 | 2.03e-02 | 1.47e-02 | 38 |
hsa041421 | Colorectum | SER | Lysosome | 38/1580 | 132/8465 | 2.87e-03 | 2.03e-02 | 1.47e-02 | 38 |
hsa0414222 | Esophagus | ESCC | Lysosome | 102/4205 | 132/8465 | 5.11e-11 | 7.13e-10 | 3.65e-10 | 102 |
hsa0414232 | Esophagus | ESCC | Lysosome | 102/4205 | 132/8465 | 5.11e-11 | 7.13e-10 | 3.65e-10 | 102 |
hsa041422 | Liver | HCC | Lysosome | 100/4020 | 132/8465 | 2.32e-11 | 4.31e-10 | 2.40e-10 | 100 |
hsa041423 | Liver | HCC | Lysosome | 100/4020 | 132/8465 | 2.32e-11 | 4.31e-10 | 2.40e-10 | 100 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DMXL2 | SNV | Missense_Mutation | c.1756N>C | p.Val586Leu | p.V586L | Q8TDJ6 | protein_coding | tolerated(0.71) | benign(0) | TCGA-A2-A04T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
DMXL2 | SNV | Missense_Mutation | c.1285N>C | p.Glu429Gln | p.E429Q | Q8TDJ6 | protein_coding | tolerated(0.32) | benign(0.143) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
DMXL2 | SNV | Missense_Mutation | c.5218G>T | p.Val1740Leu | p.V1740L | Q8TDJ6 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
DMXL2 | SNV | Missense_Mutation | c.4844A>G | p.Asn1615Ser | p.N1615S | Q8TDJ6 | protein_coding | tolerated(0.18) | possibly_damaging(0.793) | TCGA-A8-A097-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
DMXL2 | SNV | Missense_Mutation | c.6415G>C | p.Glu2139Gln | p.E2139Q | Q8TDJ6 | protein_coding | tolerated(0.67) | benign(0.098) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
DMXL2 | SNV | Missense_Mutation | c.6256G>A | p.Glu2086Lys | p.E2086K | Q8TDJ6 | protein_coding | tolerated(1) | benign(0.003) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
DMXL2 | SNV | Missense_Mutation | c.3874G>A | p.Glu1292Lys | p.E1292K | Q8TDJ6 | protein_coding | tolerated(0.56) | benign(0.001) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
DMXL2 | SNV | Missense_Mutation | novel | c.2242A>C | p.Ile748Leu | p.I748L | Q8TDJ6 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
DMXL2 | SNV | Missense_Mutation | novel | c.2026N>T | p.Thr676Ser | p.T676S | Q8TDJ6 | protein_coding | tolerated(0.24) | probably_damaging(0.916) | TCGA-AC-A8OR-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DMXL2 | SNV | Missense_Mutation | rs763981971 | c.7111C>T | p.Arg2371Trp | p.R2371W | Q8TDJ6 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |